ClinicalTrials.gg
RecruitingNCT07556588HOPE for AllUpdated Aug 12, 2026

XVIVO Heart Transplant Study in Clinical Practice

An interventional study of XVIVO Heart Assist Transport System in Heart Failure, sponsored by XVIVO Perfusion. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by XVIVO Perfusion · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Aug 2024, registered Apr 2026).
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 197 studies in Heart Failure with a site in Belgium — 27 open to participants now, 45 under way, 8 of them phase 3. Heart Failure · Belgium.

Planned enrollment
142nd of 155
20 · median 262
Started
2024
with 11 others
No phase
78 of 197
13 open now
Primary completion
2027-05
later than 21 of 44 live
Registered
196th of 197
by date

Among the 197 studies in Heart Failure with a site in Belgium, this one is the 142nd largest by planned enrollment of the 155 interventional ones that give a count, is one of 12 that started in 2024, is one of 78 with no phase, reaches primary completion later than 21 of the 44 other live ones, and was the 196th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

27 of the 197 studies in Heart Failure with a site in Belgium are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies in Heart Failure with a site in Belgium, or all of them as a file.
02

Study summary

HOPE for All is a clinical investigation to support the use of hypothermic oxygenated perfusion (HOPE) using a revised XVIVO Heart Assist Transport System in a real- world setting.

The trial will investigate the application of HOPE in a broad population of Donation after Brain Death (DBD) and Donation after Circulatory Death (DCD) donor hearts transplanted to any listed adult patient.

The hypothesis is that the use of HOPE is safe and feasible for any adult patient awaiting a heart transplantation.

Primary objective is to evaluate patient survival in the real world setting after heart transplantation, where HOPE using the revised XVIVO Heart Assist Transport System is used for donor heart preservation.

Secondary objective(s) are to evaluate patient outcomes and graft function post-transplant.

HOPE for All is a prospective, single-armed single-centre proof-of-consept trial.

Read the detailed description

HOPE for All will include a total of 20 subjects transplanted with donor hearts using the revised XVIVO Heart Assist Transport System and will evaluate transplant outcomes such as patient survival, post-transplant complications and graft function for a period of 12 months post-transplant.

The investigation will be conducted at 1 heart transplant center in Belgium who has thorough experience using the XVIVO Heart Assist Transport System for both DBD and DCD transplants.

The study will not include a control group as this is a proof-of-concept study

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Recipient:

  1. Age ≥18 years
  2. Signed form
  3. Accepted or listed for heart transplantation

Inclusion Criteria Heart Donor:

  1. Accepted as a heart donor by the transplant team based on current standard of care criteria
  2. DBD or DCD Maastricht category III or euthanasia donors

Exclusion Criteria Recipient:

  1. Not able to understand the information provided during the informed consent procedure
  2. Combined organ transplantation candidates

Exclusion Criteria Heart Donor:

  1. Functional warm ischemia time (FWIT) > 30 minutes (DCD).
  2. Donor cardiac arrest does not occur within 120 minutes from Withdrawal of life sustaining therapy (DCD)
  3. Deviations from Donor end of life treatment protocol as defined by local standard operating procedures
  4. Donor heart assessed as not transplantable by the responsible clinician at any time point during the donation or procurement procedure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Preservation of DBD and DCD hearts for transplant.

    Device: XVIVO Heart Assist Transport System

Interventions

  • DeviceXVIVO Heart Assist Transport System

    Revised XHAT

    Also known as: Hypothermic oxygenated perfusion - HOPE, Direct procurment, Non-Ischemic Heart Preservation NIHP

06

What researchers measure

Primary outcomes

  1. Patient Survival

    Time frame: 30 days post-transplant

Secondary outcomes

  1. Cardiac related mortality at 30 days post-transplant

    Time frame: 30 days post-transplant

  2. Incidence of Mechanical circulatory support within 30 days post-transplant

    Time frame: 30-days post-transplant

  3. Incidence of severe Primary Graft Dysfunction (PGD) at 24 hours post-transplant

    Time frame: 24 hours post-transplant

  4. Incidence of Primary Graft Dysfunction (PGD) RV at 24 hours post-transplant

    Time frame: 24 hours post-transplant

  5. Cardiac function as assessed by left ventricular ejection fraction (LVEF) at 24 hours and 30 days post-transplant

    Time frame: 24 hours and 30 days post-transplant

  6. Duration of initial ICU stay after the index procedure

    Time frame: 30-days post-transplant

  7. Incidence of biopsy proven rejections > 1 ACR (leading to changed immunosuppressive regime) within 30 days post-transplant

    Time frame: 30 days post-transplant

  8. Incidence of hearts perfused on the investigational device which is not used for transplantation

    Time frame: From enrollment to the end of recruitment

  9. Cardiac related mortality at 6 and 12 months post-transplant

    Time frame: 6 and 12 months post-transplant

  10. Cardiac function as assessed by left ventricular ejection fraction (LVEF) at 6 and 12 months post-transplant

    Time frame: 6 and 12 months post-transplant

  11. Number of days until hospital discharge from index procedure 6 and 12 months post-transplant

    Time frame: 6 and 12 months post-transplant

  12. Incidence of biopsy proven rejections > 1 ACR leading to changed immunosuppressive regime within 12 months post-transplant

    Time frame: Within 12 months post-transplant

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for May 2027, 33 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 33 months is close to that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Apr 29, 2026
StartActual
Aug 3, 2024
Primary completionEst.
May 15, 2027
CompletionEst.
Apr 15, 2028
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07556588
Lead sponsor
XVIVO Perfusion
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Aug 3, 2024
Primary completion
May 15, 2027 (estimated)
Completion
Apr 15, 2028 (estimated)
Last update
Aug 12, 2026

Study contacts

Filip Rega, MD, PhD
Contact
filip.rega@uzleuven.be
+32 16 34 08 43
Janne Brouckaert, MD
Contact
Janne.brouckaert@uzleuven.be
+3216346278

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion